Avior Wealth Management LLC Boosts Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Avior Wealth Management LLC increased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 33.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,670 shares of the company’s stock after purchasing an additional 1,183 shares during the quarter. Avior Wealth Management LLC’s holdings in Vaxcyte were worth $293,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Swiss National Bank lifted its stake in Vaxcyte by 8.9% in the first quarter. Swiss National Bank now owns 50,000 shares of the company’s stock valued at $1,208,000 after buying an additional 4,100 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Vaxcyte by 31.3% in the first quarter. JPMorgan Chase & Co. now owns 26,792 shares of the company’s stock valued at $647,000 after buying an additional 6,390 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Vaxcyte by 4.7% in the first quarter. Bank of New York Mellon Corp now owns 152,364 shares of the company’s stock valued at $3,680,000 after buying an additional 6,891 shares during the last quarter. MetLife Investment Management LLC lifted its stake in Vaxcyte by 58.5% in the first quarter. MetLife Investment Management LLC now owns 23,689 shares of the company’s stock valued at $572,000 after buying an additional 8,743 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in Vaxcyte by 8.2% in the first quarter. Rhumbline Advisers now owns 50,789 shares of the company’s stock valued at $1,227,000 after buying an additional 3,852 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Price Performance

NASDAQ:PCVX opened at $60.83 on Friday. The stock’s 50 day simple moving average is $69.39 and its 200-day simple moving average is $60.93. Vaxcyte, Inc. has a 12-month low of $41.57 and a 12-month high of $82.04.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same period in the previous year, the business earned ($0.73) earnings per share. On average, analysts forecast that Vaxcyte, Inc. will post -4.18 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Bank of America boosted their price objective on Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 2nd. Needham & Company LLC reissued a “buy” rating and issued a $95.00 target price on shares of Vaxcyte in a report on Wednesday, April 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Friday, January 12th. Four investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte presently has a consensus rating of “Buy” and an average price target of $78.50.

Insider Buying and Selling

In related news, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $63.92, for a total transaction of $958,800.00. Following the transaction, the chief executive officer now owns 375,814 shares of the company’s stock, valued at $24,022,030.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Vaxcyte news, SVP Mikhail Eydelman sold 1,667 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $73.87, for a total value of $123,141.29. Following the sale, the senior vice president now owns 20,710 shares of the company’s stock, valued at $1,529,847.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $63.92, for a total value of $958,800.00. Following the completion of the sale, the chief executive officer now directly owns 375,814 shares in the company, valued at approximately $24,022,030.88. The disclosure for this sale can be found here. Insiders have sold 101,577 shares of company stock valued at $6,940,475 over the last quarter. Company insiders own 3.60% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.